Medical Devices: What Those Paying Are Saying

The Affordable Care Act is shifting the economic risks of care from the payors to the providers, and medtech companies will be forced to find new sales and distribution channels, new ways of defining clinical and economic benefit, and new offerings wrapped around devices to enhance both their clinical and economic value. At the IN3 meeting in October 2013, executives from both the payor and provider communities discussed how medtech companies should respond to these new dynamics.

Lisa Suennen, a partner at the venture capital firm the Psilos Group, has sat through countless pitches from medical device companies seeking funding. Psilos is a diversified fund focused on health care, and its current $300 million fund invests across health care services, health care IT, and medical devices, with medical devices tending to account for 34% of the mix. Before becoming a founding partner of Psilos in 1998, Suennen had spent 10 years as an executive at Merit Behavioral Care, a specialty health care management organization. Because she operates in both the service and medical device worlds, Suennen says she has realized how insular the thinking of the medical device world is and how out of sync it is with the way health systems operate. “I often see medtech start-ups focused on getting a reimbursement code. But getting a code isn’t the same thing as getting it paid for and too few really understand that.”

Medtech companies are certainly sensitive to the pressures of health care reform and they’re conscious that their products need to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo